SCHEMBL3456967

SCHEMBL3456967

CCCC[CH]c1ccccc1CCl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALDH1A1 P00352 2/20 0.33
LIPG Q9Y5X9 1/20 0.33
POLB P06746 1/20 0.32
TSHR P16473 4/20 0.32
HTT P42858 2/20 0.31
BID P55957 3/20 0.31
BCL2L1 Q07817 3/20 0.31
MCL1 Q07820 3/20 0.31
BAK1 Q16611 3/20 0.31
CYP1A2 P05177 1/20 0.30
NFKB1 P19838 1/20 0.30
CYP2C19 P33261 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MAPT P10636 1/20 0.30
NPC1 O15118 1/20 0.30
ALOX12 P18054 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15563320 0.85 POLB (0.37) CYP2D6CYP3A4CYP2C9LIPGPOLB
SCHEMBL15563302 0.83 CYP3A4 (0.39) CYP2D6CYP3A4CYP2C9LIPGTSHR
SCHEMBL15563153 0.83 CYP3A4 (0.46) CYP2D6CYP3A4CYP2C9LIPGBID
SCHEMBL15563463 0.81 LIPG (0.49) CYP2D6CYP3A4CYP2C9LIPGBID
SCHEMBL15563129 0.80 LIPG (0.51) CYP2D6CYP3A4CYP2C9LIPGBID
SCHEMBL9248747 0.79 LIPG (0.38) CYP2D6CYP3A4CYP2C9LIPGPOLB
SCHEMBL8113452 0.79 GABRA1 (0.40) CYP2D6CYP3A4CYP2C9LIPG
SCHEMBL15563144 0.78 CYP3A4 (0.45) CYP2D6CYP3A4CYP2C9LIPGBID
SCHEMBL15563104 0.78 LIPG (0.49) CYP2D6CYP3A4CYP2C9LIPGBID
SCHEMBL11014049 0.78 LIPG (0.41) CYP2D6CYP3A4CYP2C9LIPGBID

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2263995-A1 Para-tert-butylcalix[6]arenes with triacid fuctional groups in positions 2, 4 and 6, as well as supported liquid membranes and support material comprising such membranes and their use INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE (I.R.S.N.) (FR) 2010-12-22 EP disclosed
US-20090095681-A1 P-TERT-BUTYLCALIX[6]ARENES WITH TRIACIDIC FUNCTIONS AT 2, 4 AND 6, SUPPORTED LIQUID MEMBRANES AND SUPPORT MATERIALS COMPRISING THE SAME AND USE THEREOF CHELATOR (FR) 2009-04-16 US disclosed
EP-1885682-A2 P-TERT-BUTYLCALIX[6]ARENES WITH TRIACIDIC FUNCTIONS AT 2, 4 AND 6 SUPPORTED LIQUID MEMBRANES SUPPORT MATERIALS COMPRISING THE SAME AND USE THEREOF CHELATOR (FR) 2008-02-13 EP disclosed
WO-2006123051-A2 P-TERT-BUTYLCALIX[6]ARENES WITH TRIACIDIC FUNCTIONS AT 2, 4 AND 6 SUPPORTED LIQUID MEMBRANES SUPPORT MATERIALS COMPRISING THE SAME AND USE THEREOF CHELATOR (FR) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090095681-A1 P-TERT-BUTYLCALIX[6]ARENES WITH TRIACIDIC FUNCTIONS AT 2, 4 AND 6, SUPPORTED LIQUID MEMBRANES AND SUPPORT MATERIALS COMPRISING THE SAME AND USE THEREOF TERT, SLC6A6, SLC26A3 CYP2D6 1034/4885CYP3A4 2368/4885CYP2C9 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.